Harrow Inc
HROW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.49B
Close$
$13.51
65.2% downside
Current Fair Value
65.2% downsideOvervalued by 65.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.49 Billion |
|---|---|
| Enterprise Value | $1.71 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.26 |
| Outstanding Shares | 37,350,401 |
Return
| Return on Equity | -244.91% |
|---|---|
| Return on Assets | -8.93% |
| Return on Invested Capital | -7.37% |
Valuation & Multiples
| P/E Ratio | -40.33 |
|---|---|
| PEG | 9.05 |
| Price to Sales | 5.55 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.2 |
| Enterprise Value to EBIT | -73.75 |
| Enterprise Value to Net Income | -46 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 19.79 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$70.35 M
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$0.25
Average shareholder expectationRevenue Estimate
$100.78 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 50.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.30%▼ 42.94% |
|---|---|
| Total Invested | $241.79M▼ 67.99% |
| Investors Holding | 81▼ 145.00% |
ESG Score
No data
About Harrow Health Inc
125 employeesHarrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...